Invivyd Business Summary

Invivyd, Inc. (IVVD) is a commercial-stage biopharmaceutical company that generates revenue primarily through the sale of monoclonal antibody (mAb) therapies, specifically its lead product PEMGARDA (pemivibart), which is authorized for COVID-19 prophylaxis. The company’s business model leverages a proprietary integrated technology platform that combines viral surveillance and predictive modeling with advanced antibody engineering to develop a pipeline of "variant-agnostic" treatments. Primary business segments are focused on infectious disease prophylaxis and treatment, with a robust late-stage pipeline featuring VYD2311 for COVID-19 and preclinical candidates for Respiratory Syncytial Virus (RSV) and measles. Direct competitors include Vir Biotechnology, Novavax, Brii Biosciences, and AstraZeneca; Invivyd occupies a specialized market niche by providing mAb-mediated protection specifically for immunocompromised and high-risk populations who exhibit suboptimal responses to traditional vaccines. Originally founded in 2020 as Adagio Therapeutics, a spin-out from the antibody discovery leader Adimab, the company was established by a founding team including Tillman Gerngross and Laura Walker. Current leadership is anchored by William Duke, Jr., who serves as Chief Financial Officer and Principal Executive Officer, bringing over 25 years of biotech leadership experience from firms such as Apexigen and Kaleido Biosciences. The executive team was significantly strengthened in March 2026 with the appointment of renowned Harvard epidemiologist Michael Mina, M.D., Ph.D., as Chief Medical Officer, working alongside Chief Scientific Officer Robert Allen and Chief Commercial Officer Timothy Lee. Invivyd is governed by a board led by Chairman Marc Elia and includes Ajay Royan, co-founder of Mithril Capital, with major institutional backing from Janus Henderson, Perceptive Advisors, and RA Capital Management.